Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. Based on this data, the Company is initiating the Investigational New Drug (IND) application process with the U.S. Food and Drug Administration (FDA).

"We are very pleased with these preliminary results from our VMAT2 Phase IIa study," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences.  "Over the twelve days of treatment with our VMAT2 inhibitor, subjects showed a marked improvement in abnormal hyperkinetic movements. The drug was generally well tolerated and showed the desired pharmacokinetic profile previously demonstrated in two Phase I studies."

The open-label Phase IIa study was designed to assess efficacy, safety and tolerability of NBI-98854 in up to ten schizophrenia patients who have moderate to severe Tardive Dyskinesia over a twelve-day period. The impact on the dyskinesia was assessed utilizing the Abnormal Involuntary Movement Scale (AIMS). The dosing regimen consisted of three, four-day periods of NBI-98854 at increasing doses of 12.5mg, 25mg and 50mg administered once daily. After discontinuation of NBI-98854, a seven-day washout period was followed by a final assessment. The study inclusion criteria included a baseline total score of at least nine on the first seven components of the AIMS, with at least two body regions receiving scores of moderate (3) or severe (4). For this cohort of six subjects, the mean baseline score was 14.3 (AIMS total items 1-7, possible total score of 28).

After the twelve days of dosing in six subjects, the mean AIMS score decreased to 8.4, a reduction of 41.3%. Reduction in abnormal involunta
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... trademark owners have been battling search engines and online ... that trigger online advertising. Two recent and conflicting rulings ... law to the new keyword technology can be a ... a recent court ruling on advertising triggered by the ...
... high gas costs and poor sport utility vehicle (SUV) ... at the University of Wisconsin-Madison has spent the last ... fuel-efficient SUVs in North America. The principles behind the ... incorporated into mass-production hybrid SUVs. , ,The effort is ...
... Wis. - Before Gov. Jim Doyle ... of stem cell research, a key Republican legislator had already ... projects. , ,The projects, which now are the subject of ... the Doyle Administration by State Sen. Ted Kanavas , ...
Cached Biology Technology:Keyword advertisers win some, lose some 2Keyword advertisers win some, lose some 3Keyword advertisers win some, lose some 4Keyword advertisers win some, lose some 5UW-Madison hybrid-vehicle team places second nationally 2GOP lawmaker faults Doyle for IT problems 2GOP lawmaker faults Doyle for IT problems 3
(Date:4/14/2014)... RICHLAND, Wash. Think of the pressure change you feel ... tall building. Imagine how you,d feel if that elevator carried ... Everest in the blink of an eye. , That,s ... the turbulent waters near a dam. For some, the change ... die or are seriously injured. , In an article in ...
(Date:4/14/2014)... collaborators have reconstructed the phylogeny and biological history for ... region of the Earth surrounding the equator. In-depth ... species new to science, each having previously been confused ... on this group began, Sturnira has grown ... were described in a new study, published online in ...
(Date:4/14/2014)... an animal stops to look around its environment, neuroscientists ... the birth of a memory. , Using lab ... neuroscience in the Zanvyl Krieger Mind/Brain Institute at Johns ... the rats frequently paused to inspect their environment with ... this behavior activated a place cell in their brain, ...
Breaking Biology News(10 mins):Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3Neuroscientists: Brain activity may mark the beginning of memories 2Neuroscientists: Brain activity may mark the beginning of memories 3
... years of exhaustive analysis led by a University of Alberta ... exploded from just a handful to more than 4,000. ... ailing patient looks at something like 10 to 20 chemicals," ... blood chemicals that doctors can potentially look at to diagnose ...
... 24, 2011 For a week in March, the permanent ... and other attractions becomes the world capital of science as ... 241st National Meeting & Exposition of the American Chemical Society ... world,s largest scientific society, and the sessions in balmy Anaheim ...
... identified a strain of probiotic bacteria that may be useful ... They report their findings in the February 2011 issue of ... H. pylori is considered one of the major risk ... ulcers," write the researchers. "Currently, antibiotic-based treatment for ...
Cached Biology News:Researcher lists more than 4,000 components of blood chemistry 2American Chemical Society National Meeting & Exposition, March 27-31, Anaheim, Calif. 2Probiotic identified to treat ulcers 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: